Kamada’s latest acquisition positions the company as a global leader
Categories: Corporate and M&A, Hi-Tech
Nasdaq-listed KAMADA, a plasma-derived biopharmaceutical company, acquired a portfolio of four FDA approved plasma-derived hyperimmune commercial products from Saol Therapeutics for a purchase price of up to $160 million.
The strategic transformational transaction positions the company as a global leader in the plasma-derived hyperimmune market.
The Naschitz Brandes Amir team representing Kamada was by Senior Partner Sharon Amir, together with partners Tuvia Geffen and Avishai Eliash, and associate Michal Gomel.
Mayer Brown LLP served as legal counsel to Saol Therapeutics.
